Literature DB >> 33439725

Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features.

Nicholas Meti1,2, Khadijeh Saednia3, Andrew Lagree4, Sami Tabbarah4, Majid Mohebpour4, Alex Kiss5, Fang-I Lu6, Elzbieta Slodkowska6, Sonal Gandhi1,7, Katarzyna Joanna Jerzak1,7, Lauren Fleshner4, Ethan Law4, Ali Sadeghi-Naini2,3,4, William T Tran2,4,8.   

Abstract

PURPOSE: Neoadjuvant chemotherapy (NAC) is used to treat locally advanced breast cancer (LABC) and high-risk early breast cancer (BC). Pathological complete response (pCR) has prognostic value depending on BC subtype. Rates of pCR, however, can be variable. Predictive modeling is desirable to help identify patients early who may have suboptimal NAC response. Here, we test and compare the predictive performances of machine learning (ML) prediction models to a standard statistical model, using clinical and pathological data.
METHODS: Clinical and pathological variables were collected in 431 patients, including tumor size, patient demographics, histological characteristics, molecular status, and staging information. A standard multivariable logistic regression (MLR) was developed and compared with five ML models: k-nearest neighbor classifier, random forest (RF) classifier, naive Bayes algorithm, support vector machine, and multilayer perceptron model. Model performances were measured using a receiver operating characteristic (ROC) analysis and statistically compared.
RESULTS: MLR predictors of NAC response included: estrogen receptor (ER) status, human epidermal growth factor-2 (HER2) status, tumor size, and Nottingham grade. The strongest MLR predictors of pCR included HER2+ versus HER2- BC (odds ratio [OR], 0.13; 95% CI, 0.07 to 0.23; P < .001) and Nottingham grade G3 versus G1-2 (G1-2: OR, 0.36; 95% CI, 0.20 to 0.65; P < .001). The area under the curve (AUC) for the MLR was AUC = 0.64. Among the various ML models, an RF classifier performed best, with an AUC = 0.88, sensitivity of 70.7%, and specificity of 84.6%, and included the following variables: menopausal status, ER status, HER2 status, Nottingham grade, tumor size, nodal status, and presence of inflammatory BC.
CONCLUSION: Modeling performances varied between standard versus ML classification methods. RF ML classifiers demonstrated the best predictive performance among all models.

Entities:  

Year:  2021        PMID: 33439725     DOI: 10.1200/CCI.20.00078

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  5 in total

1.  Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.

Authors:  Lisi M Dredze; Michael Friger; Samuel Ariad; Michael Koretz; Bertha Delgado; Ruthy Shaco-Levy; Margarita Tokar; Michael Bayme; Ravit Agassi; Maia Rosenthal; Victor Dyomin; Olga Belochitski; Shai Libson; Tamar Mizrahi; David B Geffen
Journal:  Breast Cancer Res Treat       Date:  2022-04-22       Impact factor: 4.872

2.  Development of Gene Expression-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer.

Authors:  Seongyong Park; Gwansu Yi
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

3.  Predictive Value of 18F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.

Authors:  Jang Yoo; Jaeho Lee; Miju Cheon; Sang-Keun Woo; Myung-Ju Ahn; Hong Ryull Pyo; Yong Soo Choi; Joung Ho Han; Joon Young Choi
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

Review 4.  Artificial intelligence and machine learning for medical imaging: A technology review.

Authors:  Ana Barragán-Montero; Umair Javaid; Gilmer Valdés; Dan Nguyen; Paul Desbordes; Benoit Macq; Siri Willems; Liesbeth Vandewinckele; Mats Holmström; Fredrik Löfman; Steven Michiels; Kevin Souris; Edmond Sterpin; John A Lee
Journal:  Phys Med       Date:  2021-05-09       Impact factor: 2.685

5.  Assessment of Digital Pathology Imaging Biomarkers Associated with Breast Cancer Histologic Grade.

Authors:  Andrew Lagree; Audrey Shiner; Marie Angeli Alera; Lauren Fleshner; Ethan Law; Brianna Law; Fang-I Lu; David Dodington; Sonal Gandhi; Elzbieta A Slodkowska; Alex Shenfield; Katarzyna J Jerzak; Ali Sadeghi-Naini; William T Tran
Journal:  Curr Oncol       Date:  2021-10-27       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.